HK1257884A1 - 用於在癌症患者中預測藥物反應性的方法 - Google Patents

用於在癌症患者中預測藥物反應性的方法

Info

Publication number
HK1257884A1
HK1257884A1 HK19100245.2A HK19100245A HK1257884A1 HK 1257884 A1 HK1257884 A1 HK 1257884A1 HK 19100245 A HK19100245 A HK 19100245A HK 1257884 A1 HK1257884 A1 HK 1257884A1
Authority
HK
Hong Kong
Prior art keywords
methods
cancer patients
drug responsiveness
predicting drug
predicting
Prior art date
Application number
HK19100245.2A
Other languages
English (en)
Inventor
Steen Knudsen
Original Assignee
Oncology Venture ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncology Venture ApS filed Critical Oncology Venture ApS
Publication of HK1257884A1 publication Critical patent/HK1257884A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK19100245.2A 2016-12-30 2019-01-08 用於在癌症患者中預測藥物反應性的方法 HK1257884A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662440883P 2016-12-30 2016-12-30

Publications (1)

Publication Number Publication Date
HK1257884A1 true HK1257884A1 (zh) 2019-11-01

Family

ID=60856935

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18114579.0A HK1255416B (zh) 2016-12-30 2018-11-15 預測癌症患者對藥物反應的方法
HK19100245.2A HK1257884A1 (zh) 2016-12-30 2019-01-08 用於在癌症患者中預測藥物反應性的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK18114579.0A HK1255416B (zh) 2016-12-30 2018-11-15 預測癌症患者對藥物反應的方法

Country Status (7)

Country Link
US (1) US10907214B2 (zh)
EP (1) EP3342879B1 (zh)
CN (1) CN108265106B (zh)
AU (1) AU2017258901A1 (zh)
CA (1) CA2990273A1 (zh)
DK (1) DK3342879T3 (zh)
HK (2) HK1255416B (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2123258A1 (en) 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
WO2016046640A2 (en) 2014-09-26 2016-03-31 Medical Prognosis Institute A/S Methods for predicting drug responsiveness
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
AU2018202878A1 (en) 2017-05-16 2018-12-06 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
US11851712B2 (en) * 2018-03-06 2023-12-26 Board Of Regents, The University Of Texas System Replication stress response biomarkers for immunotherapy response
CN108913773A (zh) * 2018-07-12 2018-11-30 温州医科大学 一种临床评价卵巢癌铂类药物化疗敏感性的多分子标志物及其装置与评价方法
CN111424083A (zh) * 2019-01-10 2020-07-17 北京医院 一种白血病标志物及其在白血病预后评估中的用途
WO2020146678A2 (en) * 2019-01-10 2020-07-16 Research Institute At Nationwide Children's Hospital Methods to identify and treat cisplatin-resistant ovarian cancer
MX2022001812A (es) 2019-08-12 2022-03-11 Regeneron Pharma Variantes del receptor estimulante de macrofagos 1 (mst1r) y sus usos.
CN110714078B (zh) * 2019-09-29 2021-11-30 浙江大学 一种用于ii期结直肠癌复发预测的标记基因及应用
KR102263983B1 (ko) * 2020-02-12 2021-06-11 씨비에스바이오사이언스 주식회사 간세포 종양에 있어서 소라페닙 치료의 감수성을 증가시키기 위한 분석방법
KR102222520B1 (ko) * 2020-09-04 2021-03-05 연세대학교 산학협력단 약물 반응성 예측용 조성물 및 이의 용도
CN113025713B (zh) * 2021-02-23 2022-11-22 浙江东睿生物科技有限公司 用于预测肿瘤患者对特定抗肿瘤药物的敏感性的生物标志物的应用
CN113667752A (zh) * 2021-09-09 2021-11-19 菲思特(上海)生物科技有限公司 一种用于柔红霉素代谢标志物的检测试剂盒及其检测方法和应用
CN114768091A (zh) * 2022-03-28 2022-07-22 湖南安泰康成生物科技有限公司 结肠癌治疗系统以及结肠癌治疗的交变电场发生装置
CN114948973A (zh) * 2022-04-12 2022-08-30 哈尔滨医科大学 硼替佐米与索拉非尼联合在制备治疗肾透明细胞癌药物中的用途

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4963362A (en) 1987-08-07 1990-10-16 Regents Of The University Of Minnesota Freeze-dried liposome mixture containing cyclosporin
US5956501A (en) 1997-01-10 1999-09-21 Health Hero Network, Inc. Disease simulation system and method
US7625697B2 (en) 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
WO1996010585A1 (en) 1994-09-30 1996-04-11 Inex Pharmaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
US5858397A (en) 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
US20040072722A1 (en) 2002-10-10 2004-04-15 Kornblith Paul L. Methods for assessing efficacy of chemotherapeutic agents
WO1999030686A1 (en) 1997-12-12 1999-06-24 Inex Pharmaceuticals Corp. Cationic drugs encapsulated in anionic liposomes
US20020006613A1 (en) 1998-01-20 2002-01-17 Shyjan Andrew W. Methods and compositions for the identification and assessment of cancer therapies
CA2349417A1 (en) 1998-11-05 2000-05-11 Parker Hughes Institute Ikaros isoforms and mutants
JP2000224989A (ja) * 1998-11-20 2000-08-15 Asahi Breweries Ltd 制癌剤感受性試験方法
CA2352259A1 (en) 1998-11-25 2000-06-02 British Telecommunications Public Limited Company Controlling overload of an email or voicemail messaging platform
WO2000034788A1 (en) 1998-12-08 2000-06-15 Board Of Regents, The University Of Texas System Methods for detection of antiestrogen-resistant breast cancer
WO2000035473A2 (en) 1998-12-18 2000-06-22 Scios Inc. Methods for detection and use of differentially expressed genes in disease states
US6647341B1 (en) 1999-04-09 2003-11-11 Whitehead Institute For Biomedical Research Methods for classifying samples and ascertaining previously unknown classes
US7324926B2 (en) 1999-04-09 2008-01-29 Whitehead Institute For Biomedical Research Methods for predicting chemosensitivity or chemoresistance
US6911306B1 (en) 1999-10-18 2005-06-28 Emory University TMS1 compositions and methods of use
AU2001245295A1 (en) 2000-02-17 2001-08-27 Millennum Pharmaceuticals, Inc. Methods and compositions for the identification, assessment, prevention and therapy of human cancers
US20030026831A1 (en) 2001-04-20 2003-02-06 Aparna Lakkaraju Anionic liposomes for delivery of bioactive agents
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
WO2003041681A2 (en) 2001-11-13 2003-05-22 Celator Technologies, Inc. Lipid carrier compositions with enhanced blood stability
EP1534854A4 (en) 2002-03-28 2006-11-15 Ohio Med College METHOD AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF NON-SMALL CELL LUNG CANCER USING GENE EXPRESSION PROFILES
JP2004043446A (ja) 2002-05-15 2004-02-12 Schering Ag ヒストンデアセチラーゼ抑制剤及びその使用
DE60331537D1 (de) 2002-05-17 2010-04-15 Celgene Corp Kombinationen zur behandlung von multiplem myelom
US7273620B1 (en) 2002-05-20 2007-09-25 University Of British Columbia Triggered release of liposomal drugs following mixing of cationic and anionic liposomes
US20040018525A1 (en) 2002-05-21 2004-01-29 Bayer Aktiengesellschaft Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma
US20040022842A1 (en) 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
US7718160B2 (en) 2002-07-02 2010-05-18 The Board Of Regents Of The University Of Texas System Radiolabeled compounds and liposomes and their method of making and using same
EP1643971A2 (en) 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
AU2004256425A1 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1664340A1 (en) 2003-08-08 2006-06-07 Canbas Co., Ltd. Sensitivity test to predict efficacy of anti-cancer therapies
US20050208512A1 (en) 2003-10-01 2005-09-22 The Ohio State University Research Foundation Determining the chemosensitivity of cells to cytotoxic agents
US20080113344A1 (en) 2003-10-28 2008-05-15 Ralph Wirtz Methods and Compositions for the Response Prediction of Malignant Neoplasia to Treatment
US7879545B2 (en) 2003-11-05 2011-02-01 H. Lee Moffitt Cancer Center And Research Institute, Inc. Identification of novel targets for radio sensitization using a genomic-based radiation sensitivity classifier
US20050147978A1 (en) 2003-12-30 2005-07-07 Jose Remacle Method for quantitative determination of multi-drug resistance in tumors
CN1922332B (zh) 2003-12-31 2013-06-12 宾夕法尼亚州研究基金会 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
US20050227266A1 (en) 2004-02-06 2005-10-13 Ross Douglas T Biomarker:compound correlations in cancer diagnosis and therapy
EP2295604B1 (en) 2004-02-09 2015-04-08 Thomas Jefferson University Diagnosis and treatment of cancers with microRNA located in or near cancer-associated chromosomal features
US20070270488A1 (en) 2004-03-12 2007-11-22 The Queen's University Of Belfast Treatment and Assays
WO2005094863A1 (en) 2004-03-30 2005-10-13 Den Kgl.Veterinær-Og Landbohøjskole Improvements in cancer treatment and cancer treatment efficacy prediction by blocking and decting protease inhibitors
DK2163650T3 (en) 2004-04-09 2015-11-02 Genomic Health Inc Genekspressionsmarkører for prediction of response to chemotherapy
UA86063C2 (ru) 2004-05-03 2009-03-25 Хермес Біосайенсез, Інк. Липосомы для снабжения лекарств
IL179285A (en) 2004-05-14 2011-04-28 Rosetta Genomics Ltd Micrornas and uses thereof
WO2006025411A1 (ja) 2004-08-31 2006-03-09 Astellas Pharm. Inc. 細胞内薬物送達改善リポソーム
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
US20070172844A1 (en) 2005-09-28 2007-07-26 University Of South Florida Individualized cancer treatments
WO2007050784A2 (en) 2005-10-25 2007-05-03 Celator Pharmaceuticals, Inc. Fixed ratio drug combination treatments for solid tumors
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
JP5984324B2 (ja) 2005-12-01 2016-09-06 メディカル プログノシス インスティテュート エー／エス 治療反応のバイオマーカーを同定するための方法および装置、ならびに治療効果を推定するためのその使用
WO2007081740A2 (en) 2006-01-05 2007-07-19 The Ohio State University Research Foundation Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers
US20090221435A1 (en) 2006-02-08 2009-09-03 Dharmacon, Inc. Microarray for detecting and quantifying microrna
WO2008006517A2 (en) 2006-07-13 2008-01-17 Siemens Healthcare Diagnostics Gmbh Prediction of breast cancer response to taxane-based chemotherapy
CN101557801B (zh) 2006-07-14 2013-10-30 Fmc生物聚合物联合股份有限公司 含有低分子量藻酸盐的水凝胶和从其制备的生物构建物
ES2405654T3 (es) 2006-09-21 2013-05-31 Nuclea Biomarkers Llc Perfiles de expresión asociados con el tratamiento con irinotecan
WO2008073629A2 (en) 2006-11-03 2008-06-19 Board Of Regents, The University Of Texas System Bifunctional predictors of cancer treatment sensitivity and resistance
US20080227663A1 (en) 2007-01-19 2008-09-18 Biodot, Inc. Systems and methods for high speed array printing and hybridization
WO2008112283A2 (en) 2007-03-12 2008-09-18 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Microrna profiling of androgen responsiveness for predicting the appropriate prostate cancer treatment
WO2008138578A2 (en) 2007-05-11 2008-11-20 Medical Prognosis Institute Methods, kits, and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
EP2198050A1 (en) 2007-09-14 2010-06-23 Asuragen, INC. Micrornas differentially expressed in cervical cancer and uses thereof
US20090162425A1 (en) 2007-09-19 2009-06-25 University Of Tennessee Research Foundation Methods and compositions for inhibiting undesirable cellular proliferation by targeted liposome delivery of active agents
US20100240043A1 (en) 2007-10-19 2010-09-23 Cedars-Sinai Medical Center Methods of using genetic variants to diagnose and predict inflammatory bowel disease
WO2009080437A1 (en) 2007-12-21 2009-07-02 Exiqon A/S Micro-rna based drug resistance analysis method
EP2123258A1 (en) 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
CN102002490A (zh) 2009-08-31 2011-04-06 上海市肿瘤研究所 9个用于预测原发性肝癌是否复发的microRNA标志物
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
DK177529B1 (en) 2009-10-23 2013-09-08 Bio Bedst Aps Liposomes with improved storage stability
EP2504451B1 (en) 2009-11-23 2019-06-05 Genomic Health, Inc. Methods to predict clinical outcome of cancer
US20120302626A1 (en) 2009-12-04 2012-11-29 Sandeep Dave Microrna and use thereof in identification of b cell malignancies
US9714446B2 (en) 2010-02-11 2017-07-25 Nanostring Technologies, Inc. Compositions and methods for the detection of small RNAs
WO2011098578A2 (en) * 2010-02-12 2011-08-18 Bioneer A/S Liposome system for ocular administration
US20130059015A1 (en) 2010-03-11 2013-03-07 H. Lee Moffitt Cancer Center & Research Institute Human Cancer micro-RNA Expression Profiles Predictive of Chemo-Response
WO2011116088A2 (en) 2010-03-16 2011-09-22 Nanostring Technologies, Inc. Compositions and methods for the detection of genomic features
EP2563936B1 (en) 2010-04-29 2018-03-14 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
EP2606353A4 (en) 2010-08-18 2014-10-15 Caris Life Sciences Luxembourg Holdings CIRCULATING BIOMARKERS FOR DISEASE
US20120046186A1 (en) 2010-08-20 2012-02-23 Pelham Robert J Gene Expression Markers for Prediction of Response to Platinum-Based Chemotherapy Drugs
CA2826657A1 (en) 2011-02-04 2012-08-09 Bioarray Therapeutics, Inc. Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
WO2012109233A2 (en) 2011-02-07 2012-08-16 Board Of Regents, The University Of Texas System Methods for predicting recurrence risk in breast cancer patients
WO2012163541A1 (en) 2011-06-01 2012-12-06 Medical Prognosis Institute A/S Methods and devices for prognosis of cancer relapse
WO2012178046A2 (en) 2011-06-24 2012-12-27 Nanostring Technologies, Inc. Multivariate diagnostic assays and methods for using same
US9677072B2 (en) 2011-09-14 2017-06-13 Georgetown University Methods of inhibiting proliferation of estrogen-independent cancer cells
WO2013130465A2 (en) 2012-02-27 2013-09-06 Genomic Health, Inc. Gene expression markers for prediction of efficacy of platinum-based chemotherapy drugs
EP2641916A1 (en) * 2012-03-23 2013-09-25 Centre National de la Recherche Scientifique (C.N.R.S) Novel antibodies anti-sPLA2-IIA and uses thereof
JP2016515508A (ja) * 2013-03-15 2016-05-30 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 融合タンパク質及びその方法
US9606123B2 (en) * 2013-03-29 2017-03-28 University Of Virginia Patent Foundation Compositions and methods for diagnosing and monitoring ovarian cancer progression and treatment
RU2528247C2 (ru) 2013-05-07 2014-09-10 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Способ оценки чувствительности клеток рака легкого к доксорубицину на основании уровней экспрессии маркерных генов и набор для его осуществления
WO2014195032A1 (en) 2013-06-07 2014-12-11 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
CA2926527A1 (en) * 2013-10-11 2015-04-16 Universite Laval Extracellular mitochondrial components for detecting inflammatory reactions and conditions
WO2016046640A2 (en) 2014-09-26 2016-03-31 Medical Prognosis Institute A/S Methods for predicting drug responsiveness
WO2016077579A1 (en) * 2014-11-14 2016-05-19 The Regents Of The University Of California Suppression of spla2-integrin binding for treating an inflammatory condition or suppressing cell proliferation
US20160199399A1 (en) 2015-01-09 2016-07-14 Medical Prognosis Institute A/S Methods for predicting drug responsiveness in cancer patients
US20180087113A1 (en) 2016-09-27 2018-03-29 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients

Also Published As

Publication number Publication date
EP3342879B1 (en) 2019-09-11
EP3342879A1 (en) 2018-07-04
AU2017258901A1 (en) 2018-07-19
HK1255416B (zh) 2020-04-29
CN108265106A (zh) 2018-07-10
CA2990273A1 (en) 2018-06-30
US10907214B2 (en) 2021-02-02
CN108265106B (zh) 2022-11-29
US20180202004A1 (en) 2018-07-19
DK3342879T3 (da) 2019-09-23

Similar Documents

Publication Publication Date Title
HK1257884A1 (zh) 用於在癌症患者中預測藥物反應性的方法
HK1248773A1 (zh) 用於癌症的治療和診斷方法
HK1250376A1 (zh) 用於癌症的治療和診斷方法
IL265759A (en) Therapeutic and diagnostic methods for cancer
IL261422A (en) Therapeutic and diagnostic methods for cancer
IL258931A (en) Medicinal compounds and methods
FI3198035T3 (fi) Menetelmiä lääkevasteen ennustamiseksi
IL262208A (en) Diagnostic and therapeutic methods for cancer
IL251630A0 (en) Combined therapy for use in cancer treatment
EP3292494C0 (en) SYSTEMS AND METHODS FOR PROVIDING PERSONALIZED RADIOTHERAPY
SG11201701035SA (en) Cancer diagnosis and therapy
IL260347A (en) Therapeutic antibodies against cd-9
IL259864A (en) Monomaleimide-functionalized platinum compounds for cancer therapy
HK1257519A1 (zh) 用於 galgt2 基因治療的方法和物質
IL247325A0 (en) Therapeutic methods using noribogaine and related compounds
IL258642B (en) Anti-cd43 antibody and its use for cancer treatment
IL258340A (en) Quantifying met protein for cancer treatment
EP3280330A4 (en) RISK ASSESSMENT OF THERAPEUTIC DRUGS
SG11201702260RA (en) Anti-cancer agent and cancer cell killing method
SG11201608328RA (en) Method for predicting response to therapy for cancer
GB201503533D0 (en) Cancer drug testing apparatus
GB201501202D0 (en) Novel methods for diagnosis and therapy
GB201417819D0 (en) Agents for cancer therapy
GB201509493D0 (en) Therapeutic antibody
GB201409457D0 (en) Molecules for cancer therapy